ADBiotech Statistics

Total Valuation

ADBiotech has a market cap or net worth of KRW 25.50 billion. The enterprise value is 31.74 billion.

Market Cap	25.50B
Enterprise Value	31.74B

Important Dates

The last earnings date was Wednesday, November 13, 2024.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

ADBiotech has 9.14 million shares outstanding. The number of shares has decreased by -9.99% in one year.

Current Share Class	n/a
Shares Outstanding	9.14M
Shares Change (YoY)	-9.99%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	47.07%
Owned by Institutions (%)	5.07%
Float	4.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.60
PB Ratio	4.53
P/TBV Ratio	n/a
P/FCF Ratio	46.92
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.80
EV / Sales	3.23
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	58.39

Financial Position

The company has a current ratio of 0.58, with a Debt / Equity ratio of 2.44.

Current Ratio	0.58
Quick Ratio	0.36
Debt / Equity	2.44
Debt / EBITDA	n/a
Debt / FCF	19.82
Interest Coverage	-9.38

Financial Efficiency

Return on equity (ROE) is -114.50% and return on invested capital (ROIC) is -12.68%.

Return on Equity (ROE)	-114.50%
Return on Assets (ROA)	-10.33%
Return on Capital (ROIC)	-12.68%
Revenue Per Employee	166.51M
Profits Per Employee	-141.38M
Employee Count	59
Asset Turnover	0.36
Inventory Turnover	2.46

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -12.87% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-12.87%
50-Day Moving Average	3,326.30
200-Day Moving Average	3,121.58
Relative Strength Index (RSI)	29.04
Average Volume (20 Days)	54,774

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ADBiotech had revenue of KRW 9.82 billion and -8.34 billion in losses. Loss per share was -913.00.

Revenue	9.82B
Gross Profit	3.60B
Operating Income	-4.48B
Pretax Income	-11.26B
Net Income	-8.34B
EBITDA	-3.32B
EBIT	-4.48B
Loss Per Share	-913.00

Full Income Statement

Balance Sheet

The company has 3.32 billion in cash and 10.77 billion in debt, giving a net cash position of -7.45 billion or -815.14 per share.

Cash & Cash Equivalents	3.32B
Total Debt	10.77B
Net Cash	-7.45B
Net Cash Per Share	-815.14
Equity (Book Value)	4.42B
Book Value Per Share	616.06
Working Capital	-5.76B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 655.96 million and capital expenditures -112.44 million, giving a free cash flow of 543.52 million.

Operating Cash Flow	655.96M
Capital Expenditures	-112.44M
Free Cash Flow	543.52M
FCF Per Share	59.46

Full Cash Flow Statement

Margins

Gross margin is 36.60%, with operating and profit margins of -45.56% and -84.91%.

Gross Margin	36.60%
Operating Margin	-45.56%
Pretax Margin	-114.57%
Profit Margin	-84.91%
EBITDA Margin	-33.77%
EBIT Margin	-45.56%
FCF Margin	5.53%

Dividends & Yields

ADBiotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	9.99%
Shareholder Yield	9.99%
Earnings Yield	-32.72%
FCF Yield	2.13%

Stock Splits

The last stock split was on May 26, 2021. It was a forward split with a ratio of 3.

Last Split Date	May 26, 2021
Split Type	Forward
Split Ratio	3

Scores

ADBiotech has an Altman Z-Score of -0.94. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.94
Piotroski F-Score	n/a